-
Mashup Score: 51The CRISPR Journal | Vol 7, No 2 - 9 day(s) ago
The CRISPR Journal
Source: www.liebertpub.comCategories: General Medicine News, Future of MedicineTweet
-
Mashup Score: 13Gene Editing in the Chagas Disease Vector Rhodnius prolixus by Cas9-Mediated ReMOT Control | The CRISPR Journal - 9 day(s) ago
Rhodnius prolixus is currently the model vector of choice for studying Chagas disease transmission, a debilitating disease caused by Trypanosoma cruzi parasites. However, transgenesis and gene editing protocols to advance the field are still lacking. Here, we tested protocols for the maternal delivery of CRISPR-Cas9 (clustered regularly spaced palindromic repeats/Cas-9 associated) elements to developing R. prolixus oocytes and strategies for the identification of insertions and deletions (indels) in target loci of resulting gene-edited generation zero (G0) nymphs. We demonstrate successful gene editing of the eye color markers Rp-scarlet and Rp-white, and the cuticle color marker Rp-yellow, with highest effectiveness obtained using Receptor-Mediated Ovary Transduction of Cargo (ReMOT Control) with the ovary-targeting BtKV ligand. These results provide proof of concepts for generating somatic mutations in R. prolixus and potentially for generating germ line-edited lines in triatomines,
Source: www.liebertpub.comCategories: General Medicine News, Future of MedicineTweet
-
Mashup Score: 7The State of Omics 2024, Wed, Apr 17th, 2024 @ 11:00 AM Mary Ann Liebert, Inc. publishers - 15 day(s) ago
The past two years have seen exciting advances in the world of genomics, as several companies threaten to disrupt the next-gen sequencing (NGS) establishment. Meanwhile, advances in spatial omics, single-cell biology, proteomics and multiomics are revealing new insights into complex biology in health and disease. In this 4-hour event–The State of Omics—leaders from the world of genome technology, analysis, NGS and multiomics offer a pulsating view of the rapid progress in this field. They will present on and discuss the arrival and application of groundbreaking new technologies that place the human genome into a richer biological context than ever before and offer a pulsating view of the rapid progress in this field.
Source: webinars.liebertpub.comCategories: General Medicine News, Future of MedicineTweet
-
Mashup Score: 16Arena BioWorks hiring Scientist, CRISPR and Gene Editing Technology Development in Cambridge, Massachusetts, United States | LinkedIn - 15 day(s) ago
Posted 4:13:21 PM. Arena BioWorks, located in Cambridge, MA, is a new biomedical research institute focused on…See this and similar jobs on LinkedIn.
Source: www.linkedin.comCategories: General Medicine News, Future of MedicineTweet
-
Mashup Score: 78The State of CRISPR and Gene Editing 2024, Wed, Jun 5th, 2024 @ 11:00 AM Mary Ann Liebert, Inc. publishers - 23 day(s) ago
Following the landmark approval of the first CRISPR-based cell therapy in December 2023, the CRISPR community is looking ahead to the next wave of commercial successes, fueled by continued innovation in the development of new gene editing and delivery tools and technologies. Equally exciting advances are occurring in livestock editing, xenotransplantation, and many other specialties. In The State of CRISPR and Gene Editing virtual summit, GEN proudly gathers a tantalizing line-up of luminaries from academia and industry to discuss the latest research developments, innovations, and advanced technologies that are expanding the CRISPR toolbox, delivering new therapies to patients and safeguarding our food supply. Highlights of this summit include:An opening keynote from David Liu (Broad Institute) on the state of base and prime editing.A keynote conversation with Laura Sepp-Lorenzino (CSO Intellia) as the biotech advances a pair of landmark in vivo therapies in the clinic.Talks on two cut
Source: webinars.liebertpub.comCategories: General Medicine News, Future of MedicineTweet
-
Mashup Score: 76The State of CRISPR and Gene Editing 2024, Wed, Jun 5th, 2024 @ 11:00 AM Mary Ann Liebert, Inc. publishers - 27 day(s) ago
Following the landmark approval of the first CRISPR-based cell therapy in December 2023, the CRISPR community is looking ahead to the next wave of commercial successes, fueled by continued innovation in the development of new gene editing and delivery tools and technologies. Equally exciting advances are occurring in livestock editing, xenotransplantation, and many other specialties. In The State of CRISPR and Gene Editing virtual summit, GEN proudly gathers a tantalizing line-up of luminaries from academia and industry to discuss the latest research developments, innovations, and advanced technologies that are expanding the CRISPR toolbox, delivering new therapies to patients and safeguarding our food supply. Highlights of this summit include:An opening keynote from David Liu (Broad Institute) on the state of base and prime editing.A keynote conversation with Laura Sepp-Lorenzino (CSO Intellia) as the biotech advances a pair of landmark in vivo therapies in the clinic.Talks on two cut
Source: webinars.liebertpub.comCategories: General Medicine News, Future of MedicineTweet
-
Mashup Score: 6Agenda - Genome Engineering: Research and Applications - 2 month(s) ago
Since 2010, this important FASEB Science Research Conference (SRC) has continued to focus on the field of genome and epigenome editing.
Source: web.cvent.comCategories: General Medicine News, Future of MedicineTweet
-
Mashup Score: 9Sickle Cell Salvation: The Victoria Gray Interview - 2 month(s) ago
Victoria Gray was the first patient to receive a CRISPR-based therapy for sickle cell disease through the exa-cel therapy trial.
Source: www.genengnews.comCategories: General Medicine News, Future of MedicineTweet
-
Mashup Score: 8Sickle Cell Salvation: The Victoria Gray Interview - 3 month(s) ago
Victoria Gray was the first patient to receive a CRISPR-based therapy for sickle cell disease through the exa-cel therapy trial.
Source: www.genengnews.comCategories: General Medicine News, Future of MedicineTweet
-
Mashup Score: 8Sickle Cell Salvation: The Victoria Gray Interview - 3 month(s) ago
Victoria Gray was the first patient to receive a CRISPR-based therapy for sickle cell disease through the exa-cel therapy trial.
Source: www.genengnews.comCategories: General Medicine News, Future of MedicineTweet
Our April 2024 issue is now online: https://t.co/LnDehdb9cb https://t.co/r9WyAXDgGY